Y-mAbs Therapeutics (YMAB) announced that its board of directors has appointed Michael Rossi as president and CEO and a member of the board of directors with an expected start date of November 6. Rossi brings more than 30 years of experience in the radiopharmaceutical industry more recently serving as president, Medical Group at Mirion (MIR). In connection with Rossi’s appointment, Thomas Gad, who founded Y-mAbs in 2015 and has served as president and head of business development and strategy and interim CEO of the company, will cease serving in those offices and assume the roles of vice chairman of the board of directors and chief business officer of the company, in each case effective as of Rossi’s start date.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on YMAB:
- Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
- Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
- Y-mAbs Therapeutics announces FDA clearance of CD38-SADA IND application
- Y-mAbs Announces Publication in Cancers
- Y-mAbs announces publication of naxitamab-based chemoimmunotherapy data
